The post Fake email from Rep. Moolenaar circulated as Trump-China trade talks began in Sweden appeared on BitcoinEthereumNews.com. Right before trade talks between the U.S. and China kicked off in Sweden last July, a fake email shook things up in D.C. Staff working on the House committee dealing with U.S. competition with China started getting weird questions. The confusion started after law firms, lobby groups, and U.S. agencies got an email that looked like it came from Rep. John Moolenaar. It asked for ideas on sanctions that lawmakers might use against Beijing. The problem is, Moolenaar never sent it. The email was totally bogus. But it landed at a tense moment, right as the Trump team was gearing up for another round of dead-end negotiations with China. According to the Journal, staffers couldn’t figure out who was behind the fake message, but the timing made everyone nervous. Someone clearly wanted to throw sand in the gears just as the U.S. and China tried, yet again, to fix their mess. Li Chenggang visits but dodges top U.S. officials While the fake Moolenaar email was bouncing around Washington, China was doing its own quiet thing. Li Chenggang, a top official under Vice Premier He Lifeng, flew into D.C. at the end of August. But his trip wasn’t set up by the White House. It wasn’t even cleared with top-level folks. He didn’t meet Treasury Secretary Scott Bessent or Trade Rep. Jamieson Greer. Instead, he met with lower-ranking people at the Treasury, Commerce Department, and USTR. “The meetings were not productive,” one person close to the talks said. Li stuck to China’s usual script, cut the tariffs, and lift export bans on U.S. tech. But he didn’t offer anything new. The visit didn’t push negotiations forward. It showed that Xi Jinping was sticking to a playbook: stay in the room, keep the optics good, but give up nothing. Xi’s message was… The post Fake email from Rep. Moolenaar circulated as Trump-China trade talks began in Sweden appeared on BitcoinEthereumNews.com. Right before trade talks between the U.S. and China kicked off in Sweden last July, a fake email shook things up in D.C. Staff working on the House committee dealing with U.S. competition with China started getting weird questions. The confusion started after law firms, lobby groups, and U.S. agencies got an email that looked like it came from Rep. John Moolenaar. It asked for ideas on sanctions that lawmakers might use against Beijing. The problem is, Moolenaar never sent it. The email was totally bogus. But it landed at a tense moment, right as the Trump team was gearing up for another round of dead-end negotiations with China. According to the Journal, staffers couldn’t figure out who was behind the fake message, but the timing made everyone nervous. Someone clearly wanted to throw sand in the gears just as the U.S. and China tried, yet again, to fix their mess. Li Chenggang visits but dodges top U.S. officials While the fake Moolenaar email was bouncing around Washington, China was doing its own quiet thing. Li Chenggang, a top official under Vice Premier He Lifeng, flew into D.C. at the end of August. But his trip wasn’t set up by the White House. It wasn’t even cleared with top-level folks. He didn’t meet Treasury Secretary Scott Bessent or Trade Rep. Jamieson Greer. Instead, he met with lower-ranking people at the Treasury, Commerce Department, and USTR. “The meetings were not productive,” one person close to the talks said. Li stuck to China’s usual script, cut the tariffs, and lift export bans on U.S. tech. But he didn’t offer anything new. The visit didn’t push negotiations forward. It showed that Xi Jinping was sticking to a playbook: stay in the room, keep the optics good, but give up nothing. Xi’s message was…

Fake email from Rep. Moolenaar circulated as Trump-China trade talks began in Sweden

For feedback or concerns regarding this content, please contact us at [email protected]

Right before trade talks between the U.S. and China kicked off in Sweden last July, a fake email shook things up in D.C. Staff working on the House committee dealing with U.S. competition with China started getting weird questions.

The confusion started after law firms, lobby groups, and U.S. agencies got an email that looked like it came from Rep. John Moolenaar. It asked for ideas on sanctions that lawmakers might use against Beijing. The problem is, Moolenaar never sent it.

The email was totally bogus. But it landed at a tense moment, right as the Trump team was gearing up for another round of dead-end negotiations with China.

According to the Journal, staffers couldn’t figure out who was behind the fake message, but the timing made everyone nervous. Someone clearly wanted to throw sand in the gears just as the U.S. and China tried, yet again, to fix their mess.

Li Chenggang visits but dodges top U.S. officials

While the fake Moolenaar email was bouncing around Washington, China was doing its own quiet thing. Li Chenggang, a top official under Vice Premier He Lifeng, flew into D.C. at the end of August. But his trip wasn’t set up by the White House. It wasn’t even cleared with top-level folks.

He didn’t meet Treasury Secretary Scott Bessent or Trade Rep. Jamieson Greer. Instead, he met with lower-ranking people at the Treasury, Commerce Department, and USTR.

“The meetings were not productive,” one person close to the talks said. Li stuck to China’s usual script, cut the tariffs, and lift export bans on U.S. tech. But he didn’t offer anything new. The visit didn’t push negotiations forward. It showed that Xi Jinping was sticking to a playbook: stay in the room, keep the optics good, but give up nothing.

Xi’s message was clear. China wants to look like the adult in the room without actually giving up anything. That same week, Xi was seen with leaders from India, Russia, North Korea, and others. The optics? A big show of global friendship that stood in sharp contrast to Trump’s “America First” playbook.

Trade war stuck over soybeans, fentanyl, and tariffs

Inside the talks, the same fights dragged on. China demanded that the U.S. remove its tariffs. Beijing wanted the ban lifted on American tech exports. Li repeated those points during his D.C. visit but didn’t back them up with real offers.

The fentanyl fight also got worse. Washington asked China to stop the flow of chemicals used in the drug’s production. But according to people involved, Beijing said no. They want the U.S. to first remove the 20% tariffs on China’s goods, which were slapped on because of China’s alleged role in the fentanyl trade.

And Agriculture was another war zone. Trump had told China to buy more American soybeans, but so far, Beijing hadn’t moved. U.S. officials claimed that China had been shrinking its orders for the past 18 months. They pulled meat-processing certificates, turned to other countries for grain, and stocked up early to avoid buying during the U.S. harvest season.

With the harvest just weeks away, American farmers were on edge. No big soybean orders had come in. Everyone feared China would skip U.S. crops completely.

Back on August 22, China’s ambassador to the U.S., Xie Feng, let it rip at a soybean industry event. He said America’s protectionism was “casting a shadow over China-U.S. agricultural cooperation.” That line landed hard. It wasn’t just about soybeans. It was about the whole trade mess.

Yet despite all the shouting, the two countries agreed on one small thing; they would keep current tariffs in place through early November. That meant no new penalties, no new relief. They also agreed to relax export controls on a few specific products, like rare-earth magnets from China and select U.S. tech items.

Then came a TV moment. Treasury Secretary Bessent told Fox News, “We’re very happy” with where things stood. “I think right now the status quo is working pretty well,” he added, referring to tariffs on China.

Your crypto news deserves attention – KEY Difference Wire puts you on 250+ top sites

Source: https://www.cryptopolitan.com/fake-email-trump-china-trade-talks-began/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09